PharmaBlock Sciences Nanjing Inc Class A (300725) - Total Liabilities
Based on the latest financial reports, PharmaBlock Sciences Nanjing Inc Class A (300725) has total liabilities worth CN¥645.64 Million CNY (≈ $94.48 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PharmaBlock Sciences Nanjing Inc Class A - Total Liabilities Trend (2013–2024)
This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A's total liabilities have evolved over time, based on quarterly financial data. See PharmaBlock Sciences Nanjing Inc Class A working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
PharmaBlock Sciences Nanjing Inc Class A Competitors by Total Liabilities
The table below lists competitors of PharmaBlock Sciences Nanjing Inc Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩8.60 Billion |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
|
China | CN¥1.07 Billion |
|
CAP S.A
SN:CAP
|
Chile | CL$2.94 Billion |
|
WAVE LIFE SCIENCES LTD.
F:1U5
|
Germany | €71.81 Million |
|
Henan Yicheng New Energy Co Ltd
SHE:300080
|
China | CN¥8.94 Billion |
|
Guangdong Shaoneng Group Co Ltd
SHE:000601
|
China | CN¥8.94 Billion |
|
Strive Asset Management
NASDAQ:ASST
|
USA | $26.31 Million |
|
SFL Corporation Ltd
NYSE:SFL
|
USA | $2.86 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down PharmaBlock Sciences Nanjing Inc Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of PharmaBlock Sciences Nanjing Inc Class A.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmaBlock Sciences Nanjing Inc Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmaBlock Sciences Nanjing Inc Class A (2013–2024)
The table below shows the annual total liabilities of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.95 Billion ≈ $285.01 Million |
-14.26% |
| 2023-12-31 | CN¥2.27 Billion ≈ $332.43 Million |
+3.05% |
| 2022-12-31 | CN¥2.20 Billion ≈ $322.60 Million |
+150.74% |
| 2021-12-31 | CN¥879.21 Million ≈ $128.66 Million |
+65.71% |
| 2020-12-31 | CN¥530.57 Million ≈ $77.64 Million |
+84.05% |
| 2019-12-31 | CN¥288.27 Million ≈ $42.18 Million |
+78.57% |
| 2018-12-31 | CN¥161.43 Million ≈ $23.62 Million |
+153.02% |
| 2017-12-31 | CN¥63.80 Million ≈ $9.34 Million |
+41.78% |
| 2016-12-31 | CN¥45.00 Million ≈ $6.58 Million |
+73.63% |
| 2015-12-31 | CN¥25.92 Million ≈ $3.79 Million |
+80.29% |
| 2014-12-31 | CN¥14.38 Million ≈ $2.10 Million |
-3.97% |
| 2013-12-31 | CN¥14.97 Million ≈ $2.19 Million |
-- |
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual lib… Read more